Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Q4 2024 Earnings Presentation
11 slides from Moberg Pharma Ab's earnings presentation, Feb 11, 2025
Slide 1: Year-End Report January – December 2024
Year-End Report January – December 2024 February 11th, 2025 at 3:00 p.m. CET. Dial-in: SE 010 884 80 16, US +1 646 664 1960 Access code: 223155 Anna Ljung, CEO
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Significant events during Q4 2024
Significant events during Q4 2024 • The success continues in Sweden, with Terclara® solidifying its position as the market leader. Building on this momentum, we are now taking the next step by launching in Norway. • A new terbinafine supplier has been secured for Terclara®/MOB-015. As a result, terb
Slide 4: Terclara® maintains its market-leading position in Sweden
Terclara® maintains its market-leading position in Sweden • The momentum continues from the successful launch in Sweden, where MOB- 015 under the brand name Terclara® maintains its clear market leader position. • For Q4, Terclara® reached a market share of 33% in value and 26% in units in pharmacy s
Slide 5: Market leader in Sweden
Market leader in Sweden Since the first full month of sales in April, the introduction of Terclara® has led to a 43% growth in value for the total market for Q2-Q4 Value Share % Q2-Q4 2024 Unit Share % Q2-Q4 2024 21% 21% 36% 30% 18% 21% 6% 4% 4% 5% 5% 7% 5% Source: IQVIA MIDAS, Pharmacy Sell-Out dat
Slide 6: Launch of Terclara® in Norway
Launch of Terclara® in Norway • In February, the first deliveries were made to Norwegian pharmacies, followed by targeted information campaigns for pharmacy staff and healthcare professionals. In parallel, consumer marketing will intensify ahead of the peak season, when the demand for nail fungus tr
Slide 7: Commercialization rollout of MOB-015
Commercialization rollout of MOB-015 Focus on commercialization in Europe: 1. Terbinafine now secured for a pan-European launch 2. An early Swedish launch gained valuable insights into consumer behavior, collecting patient feedback and provide user data to support direct to OTC/OTC-switches in more
Slide 8: Phase 3 results in the U.S.
Phase 3 results in the U.S. • The North American Phase 3 study was conducted at 33 study centers in the US and Canada, including a total of 384 patients, 260 patients receiving MOB-015 and 124 patients receiving vehicle. The study differs from previous studies with MOB-015, which is the basis for dr
Slide 9: Key Financials
Key Financials Last five quarters (SEK thousand) Oct-Dec Jul-sep Apr-Jun Jan-Mar Oct-Dec 2024 2024 2024 2024 2023 Launch of Terclara in Sweden Net revenue 1,027 3,855 4,109 820 - initiated in February 2024 and Cost of goods sold -1,165 -615 -1,388 -328 - Gross profit -138 3,240 2,721 492 - Norway Fe
Slide 10: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis MOB-015 has demonstrated Successful launch under brand world-leading ability to name Terclara® kill nail fungus • 76%1 of patients became fungus • Terclara® became the market free, in two phase 3-studies leader in Sweden instantly after including 8
Slide 11: Moberg Pharma AB (Publ) contact details
Moberg Pharma AB (Publ) Gustavslundsvägen 42, 5 tr. 167 51 Bromma mobergpharma.se